Gut Hastalarında Eşlik Eden Komorbiditeler

Abstract

Patients with gout frequently have multiple comorbidities, including hypertension(HT), cardiovascular disease (CVD), renal impairment, diabetes mellitus(DM), obesity, hyperlipidemia(HL) or metabolic syndrome. These comorbidities and their treatment may have an effect on the choice of therapeutic agent. This study was to identify the comorbidities of gout. The study retrospectively investigated the demographic, clinical, and biochemical variables and comorbid factors of patients diagnosed with gout who applied to the rheumatology department between December 2019 and April 2023. 384 gout patients were included (mean age 63.4 years; men 71.6%). 299 (77.9%) of the patients received a diagnosis for the first time. The number of patients with comorbidities was 319 (83.0%). Hypertension was the most common comorbidity, observed in 255 patients (58.5%). Other comorbid diseases were HL in 140 patients (36.4%), kidney disease in 132 patients (34.3%), coronary artery disease(CAD) in 120 patients (31.2%), DM in 100 patients (26.0%), heart failure in 65 patients (16.9%), osteoporosis in 45 patients (11.7%), liver disease in 26 patients (6.7%), stroke in 25 patients (6.5%), other diseases in 20 patients (5.2%), malignancy in 18 patients (4.6%) and the number of patients without any comorbidities was 65 (16.9%). Comorbidities in gout are very common and add further to the disease's morbidity and make its management challenging. Patients with gout should therefore screened for comorbidities and risk factors, which should be addressed as an important part of gout management.